Inhibikase Therapeutics, Inc. (IKT)

Inhibikase Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	139.22	56.49	9.17	7.19	40.75
Short-Term Investments	39.54	41.05	4.09	15.86	-
Cash & Short-Term Investments	178.76	97.54	13.25	23.05	40.75
Cash Growth	83.27%	636.06%	-42.51%	-43.44%	192.04%
Accounts Receivable	-	-	-	0.04	0.11
Other Current Assets	1.35	0.91	0.96	1.28	1.61
Total Current Assets	180.11	98.45	14.21	24.37	42.47
Net Property, Plant & Equipment	-	0.15	0.3	0.57	-
Other Long-Term Assets	1.1	-	-	-	-
Total Assets	181.2	98.6	14.51	24.94	42.47
Accounts Payable	1.16	0.94	0.65	1.15	1.09
Accrued Expenses	4.08	2.68	2.26	2.4	2.72
Short-Term Debt	-	-	0.38	-	0.25
Current Portion of Leases	-	0.11	0.15	0.15	-
Other Current Liabilities	3.06	-	-	-	-
Total Current Liabilities	8.3	3.73	3.44	3.7	4.05
Long-Term Leases	-	-	0.09	0.21	-
Total Long-Term Liabilities	-	-	0.09	0.21	-
Total Liabilities	8.3	3.73	3.53	3.9	4.05
Common Stock	0.13	0.07	0.01	0	0.03
Additional Paid-in Capital	315.43	189.25	77.87	68.8	68.21
Accumulated Other Comprehensive Income	0.02	-0.04	0	0.1	-
Retained Earnings	-142.68	-94.42	-66.9	-47.87	-29.82
Shareholders' Equity	172.9	94.87	10.98	21.04	38.42
Total Liabilities & Equity	181.2	98.6	14.51	24.94	42.47
Total Debt	0	0.11	0.62	0.35	0.25
Net Cash (Debt)	178.76	97.43	12.63	22.7	40.5
Net Cash Growth	83.47%	671.44%	-44.36%	-43.95%	197.05%
Net Cash Per Share	1.82	4.11	2.10	5.38	13.35
Book Value	172.9	94.87	10.98	21.04	38.42
Book Value Per Share	1.76	4.00	1.82	4.98	12.66
Tangible Book Value	172.9	94.87	10.98	21.04	38.42
Tangible Book Value Per Share	1.76	4.00	1.82	4.98	12.66

Updated Mar 26, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q